Cite
HARVARD Citation
Saviano, A. et al. (2022). Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial. Clinical and translational gastroenterology. 13 (6), pp. e00492-. [Online].